Warning Letter — Wholesale Peptide
The FDA issued a warning letter to Wholesale Peptide for distributing unapproved and misbranded drug products, specifically regarding the marketing of peptide-based substances.
Entities distributing peptide products, digital marketing compliance teams, and firms operating in the research chemical or specialty pharmaceutical space.
This enforcement action indicates continued FDA scrutiny of the peptide market and the sale of substances marketed for therapeutic use without required drug approvals. It suggests that firms distributing peptides must ensure their labeling and marketing do not imply clinical efficacy or intended use in humans, as such claims may trigger classification as unapproved new drugs.
Regulatory and QA teams should perform immediate audits of digital marketing assets and website copy to ensure product claims do not cross into unapproved new drug territory. Ensure all peptide-based products distributed for research are strictly controlled and not marketed for therapeutic use.
FDA Warning Letter issued to: Wholesale Peptide. 06/17/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/wholesale-peptide-729447-06172026
Open in openFDA / FDA.gov